- Home
- ANGH vs SNTI Comparison
ANGH vs SNTI Comparison
Compare ANGH & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGH | SNTI |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 22.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ANGH | SNTI |
|---|---|---|
| Price | $2.35 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 19.7K | ★ 254.4K |
| Earning Date | 04-30-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $96,736,848.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 85.06 | N/A |
| 52 Week Low | $2.25 | $0.80 |
| 52 Week High | $7.60 | $5.10 |
Technical Indicators
Market Signals| Indicator | ANGH | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 36.43 | 32.98 |
| Support Level | $2.29 | $0.80 |
| Resistance Level | $2.44 | $0.95 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 7.90 | 7.24 |
Price Performance
Historical ComparisonAbout ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.